Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin–resistance
syndrome, at present defined as the metabolic syndrome, whose limits were recently set. We …

Background: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks
is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C…

Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin …

Background & Aims: Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether
NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown. …

A new antigen-antibody system associated with the hepatitis B virus and immunologically
distinct from the HB surface, core, and e systems is reported. The new antigen, termed delta, …

Background Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant
antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials. Methods We …

Background & Aims: Treatment with adefovir dipivoxil for 48 weeks resulted in clinical
improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was …

This study aims to determine the presence of the components of the metabolic syndrome in
primary nonalcoholic steatohepatitis (NASH) and to assess the role of liver disease in the …

OBJECTIVES Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD),
but its superiority over nutritional treatment and antioxidants has never been …

The relations of dietary habits to insulin sensitivity and postprandial triglyceride metabolism
were evaluated in 25 patients with nonalcoholic steatohepatitis (NASH) and 25 age-, body …